Taş-Aygar Gamze, Ataş Hatice, Gönül Müzeyyen, Kartal Selda Pelin
University of Health Sciences, Etlik City Hospital, Dermatology Clinic, Ankara, Turkey.
Dermatol Pract Concept. 2024 Apr 1;14(2):e2024097. doi: 10.5826/dpc.1402a97.
The C-reactive protein to albumin ratio (CAR) lately has demonstrated as a prognostic factor and an indicator of disease activity, severity and prognosis in solid organ malignancies and inflammatory diseases. However, the effects of CAR have not been investigated in mycosis fungoides (MF) patients yet.
This study aimed to determine the potential role of CAR as a diagnostic and a prognostic indicator in MF.
We retrospectively investigated the electronic medical records of 97 patients with MF admitted to the Dermatology Clinic of Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital between January 2014 and December 2020. In total, 60 patients with MF were enrolled in the study. CAR was evaluated, patient and control group. Also, the other clinicopathological factors including age, lactate dehydrogenase, stage of disease, beta-2-microglobulin levels, and sedimentation levels were evaluated.
The median value of CAR was 0.85 (0.10-7.51) in the patient group, whereas it was 0.39 (0.0-1.11) in the control group (P < 0.001). Patients with disease progression (N = 16, 13M, 3 F) had a median value of CAR 0.84 (0.10-7.51) and the median value of CAR (N = 44) was 0.86 (0.12-4.57) in the group of patients with stable disease. The CAR value had no prognostic significance (P > 0.05).
There is no association between the CAR and progression in the stage in MF patients. But the CAR is significantly higher in patients with MF than in the control group. The CAR can be a guide for us in cases where we have difficulty in diagnosing.
C反应蛋白与白蛋白比值（CAR）最近已被证明是实体器官恶性肿瘤和炎症性疾病的预后因素以及疾病活动、严重程度和预后的指标。然而，CAR在蕈样肉芽肿（MF）患者中的作用尚未得到研究。
本研究旨在确定CAR作为MF诊断和预后指标的潜在作用。
我们回顾性调查了2014年1月至2020年12月期间在健康科学大学迪斯科皮·耶尔德勒姆·贝亚齐特培训和研究医院皮肤科门诊收治的97例MF患者的电子病历。总共60例MF患者纳入研究。评估了患者组和对照组的CAR。此外，还评估了其他临床病理因素，包括年龄、乳酸脱氢酶、疾病分期、β2微球蛋白水平和血沉水平。
患者组CAR的中位数为0.85（0.10 - 7.51），而对照组为0.39（0.0 - 1.11）（P < 0.001）。疾病进展患者（N = 16，13男，3女）的CAR中位数为0.84（0.10 - 7.51），疾病稳定患者组（N = 44）的CAR中位数为0.86（0.12 - 4.57）。CAR值无预后意义（P > 0.05）。
MF患者中CAR与疾病分期进展之间无关联。但MF患者的CAR显著高于对照组。在诊断困难的情况下，CAR可为我们提供指导。
